Improvement of patient convenience in treatment with growth hormone.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Patient compliance is of vital importance for the outcome of any medical therapy.

Compliance is a problem especially in the treatment of non-life-threatening conditions, such as growth retardation in children, where motivation can be low and the rewards delayed.

Who Took Part

PubMed indexes the participants as children, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

What Was Measured

Patient compliance is of vital importance for the outcome of any medical therapy.

PubMed files the paper under topics including Growth Disorders, Growth Hormone, Injections, Patient Acceptance of Health Care and Patient Compliance.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1994 (The Journal of pediatric endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.